Search

Puma Biotechnology Inc

Geschlossen

BrancheGesundheitswesen

9.09 -1.84

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.06

Max

9.35

Schlüsselkennzahlen

By Trading Economics

Einkommen

12M

8.2M

Verkäufe

12M

57M

KGV

Branchendurchschnitt

18.24

57.366

EPS

0.16

Gewinnspanne

14.493

Angestellte

179

EBITDA

14M

14M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-35.62% downside

Dividenden

By Acuity

Nächstes Ergebnis

5. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

67M

471M

Vorheriger Eröffnungskurs

10.93

Vorheriger Schlusskurs

9.09

Nachrichtenstimmung

By Acuity

50%

50%

167 / 340 Ranking in Healthcare

Puma Biotechnology Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Aug. 2026, 20:07 UTC

Puma Biotechnology Inc shares are higher, supported by positive market conditions despite a slight pullback from earlier session highs. No specific news was identified.

24. Aug. 2026, 21:01 UTC

Puma Biotechnology Inc. shares are higher in after-market hours, supported by a rebound in the bond market as Treasury yields decline.

21. Aug. 2026, 19:51 UTC

Puma Biotechnology shares are higher today, driven by gains in the Biotechnology sub-sector. The stock remains near the upper end of its one-month trading range.

20. Aug. 2026, 20:06 UTC

Puma Biotechnology Inc shares are lower today, with no specific news identified for the decline. The stock remains above its 20-day moving average.

19. Aug. 2026, 19:26 UTC

Puma Biotechnology Inc shares are higher since Tuesday's close, maintaining a cumulative return above the 20-day moving average amid no specific news.

18. Aug. 2026, 20:01 UTC

Puma Biotechnology Inc's shares are higher today, reflecting strong momentum since Monday's close, despite a slight pullback from an earlier session high.

13. Aug. 2026, 19:26 UTC

Puma Biotechnology Inc shares are lower today, following an early peak. Broader market data showed rising jobless claims and flat producer price index growth.

12. Aug. 2026, 19:46 UTC

Puma Biotechnology Inc shares are higher today, supported by positive market sentiment following a favorable inflation report. Earlier, shares pulled back from session highs.

11. Aug. 2026, 22:01 UTC

Puma Biotechnology Inc shares declined in after-market trading, continuing a downward trend since Tuesday's close, amid no specific news to explain the movement.

10. Aug. 2026, 20:06 UTC

Puma Biotechnology Inc. shares are lower today, reflecting broader market trends amid an unexpected decline in U.S. jobs and inflation reassessments.

7. Aug. 2026, 20:02 UTC

News

Puma Biotechnology shares rise following strong earnings and TD Cowen's price target increase to $6.00. Trading volume indicates heightened investor interest.

6. Aug. 2026, 19:26 UTC

Puma Biotechnology Inc shares are higher Thursday, maintaining upward momentum after three consecutive gains, despite a pullback earlier in the session.

5. Aug. 2026, 21:51 UTC

News

Puma Biotechnology shares are trading lower in after-market hours following the grant of stock awards to new employees, which may dilute existing shareholder value.

4. Aug. 2026, 19:56 UTC

Puma Biotechnology Inc is trading higher today, benefiting from a decline in crude oil prices that eased inflation concerns. Shares earlier pulled back from a session high.

3. Aug. 2026, 19:51 UTC

Puma Biotechnology Inc shares are lower today, reflecting a decline since Friday. The stock saw significant volatility, initially rising before dropping sharply.

31. Juli 2026, 19:16 UTC

Puma Biotechnology Inc shares are lower today, continuing a decline since Thursday's close. The stock is trading near the lower end of its one-month range.

30. Juli 2026, 18:31 UTC

Puma Biotechnology Inc shares are higher as the overall market recovers from recent declines. The stock remains below its 20-day moving average.

29. Juli 2026, 18:23 UTC

Puma Biotechnology Inc shares are lower amid broader market weakness as investors await the Federal Reserve's interest rate decision this afternoon.

28. Juli 2026, 18:06 UTC

Puma Biotechnology shares are lower amid broader market trends, influenced by declines in Asian markets, particularly in technology sectors.

27. Juli 2026, 19:46 UTC

Puma Biotechnology Inc shares are higher, reflecting broader market gains amid a significant decline in crude oil prices following geopolitical developments.

24. Juli 2026, 19:26 UTC

Puma Biotechnology Inc. shares are roughly flat as no specific news emerged during Friday's trading session, fluctuating within a routine range.

23. Juli 2026, 20:06 UTC

Puma Biotechnology Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday's close amid no specific news identified.

22. Juli 2026, 22:51 UTC

Puma Biotechnology Inc shares are trading higher in after-market hours, building on earlier gains. The stock remains above its 20-day moving average.

21. Juli 2026, 18:02 UTC

Puma Biotechnology Inc shares are higher during Tuesday's session, continuing a positive trend since Monday. The stock remains above its 20-day moving average.

20. Juli 2026, 20:06 UTC

Puma Biotechnology Inc shares are lower today, having reached a mid-day low of -4.46%. No specific news has been identified to explain the decline.

Peer-Vergleich

Kursveränderung

Puma Biotechnology Inc Prognose

Kursziel

By TipRanks

-35.62% Nachteil

12-Monats-Prognose

Durchschnitt 6 USD  -35.62%

Hoch 6 USD

Tief 6 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Puma Biotechnology Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

1 ratings

0

Buy

1

Halten

0

Sell

Stimmung

By Acuity

167 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat